Volume 14, Number 10—October 2008
Research
Prophylaxis after Exposure to Coxiella burnetii
Claire E. Moodie
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
, Herbert A. Thompson, Martin I. Meltzer, and David L. SwerdlowTable 3
Total medical cases averted because of postexposure prophylaxis*
| Population | No. cases averted |
|---|---|
| General population | |
| All cases of illness | 39,990 |
| Severe illness | 10,650 |
| Deaths |
480 |
| High-risk population | |
| All cases of illness | 39,990 |
| Severe illness | 29,510 |
| Deaths |
3,538 |
| Pregnant women† | |
| All cases of illness | 66,210 |
| Severe illness | 53,300 |
| Deaths | 22,394 |
*Accounting for best estimate drug-related adverse events, 82% drug efficacy, and 100% exposure.
†Includes the outcome of the unborn child.
